Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Study acronym: ECHELON-3
StatusActive, Not Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 116 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Results posted: Oct 21, 2026 Show 4 more changesShow less
    • Enrollment target: 239 to 240
    • Secondary endpoints: 6 to 11
    • Primary endpoint revised
    • Site details revised at 19 of 143 sites
  2. Study sites: 145 to 143
    • Primary completion date: Jan 12, 2026 to Jan 23, 2026
    v115
  3. Trial sites reduced: 171 → 145 locations
    • Primary completion moved earlier from Dec 31, 2026 to Jan 12, 2026
    • Enrollment target: 238 to 239
    v114
  4. Study sites revised (171)v113
  5. Primary and study completion dates: Nov 18, 2025 to Dec 31, 2026
    • Enrollment target: 239 to 238
    • Study sites: 185 to 171
    v112
Show 45 earlier versionsHide 45 earlier versions
  1. Primary and study completion dates: Nov 30, 2025 to Nov 18, 2025v111
  2. Site details revised at 1 of 185 sitesv110
  3. Enrollment target: 241 to 239
    • Study sites: 172 to 185
    v109
  4. 2 versions Re-verified since May 12, 2025, no change to tracked fieldsv107-v108
  5. Primary completion date: May 31, 2025 to Nov 30, 2025
    • Enrollment target: 240 to 241
    • Study completion date: Apr 30, 2027 to Nov 30, 2025
    v106
  6. Lead sponsor: Seagen Inc. to Seagen, a wholly owned subsidiary of Pfizerv105
  7. Re-verified, no change to tracked fieldsv104
  8. Site details revised at 1 of 172 sitesv103
  9. 7 versions Re-verified since Jul 22, 2024, no change to tracked fieldsv96-v102
  10. Study sites revised (172)v95
  11. 3 versions Re-verified since Jun 3, 2024, no change to tracked fieldsv92-v94
  12. Site details revised at 1 of 172 sitesv91
  13. Site details revised at 2 of 172 sitesv90
  14. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 225 to confirmed 240
    • Site details revised at 172 of 172 sites
    v89
  15. Site contacts updated at 1 of 172 sitesv88
  16. Site details revised at 13 of 172 sitesv87
  17. Site details revised at 12 of 172 sitesv86
  18. Study sites: 171 to 172v85
  19. Site details revised at 2 of 171 sitesv84
  20. Primary completion date: Oct 31, 2023 to May 31, 2025
    • Site contacts updated at 1 of 171 sites
    v83
  21. Site details revised at 1 of 171 sitesv82
  22. Site contacts updated at 1 of 171 sitesv81
  23. Site details revised at 1 of 171 sitesv80
  24. Enrollment target: 400 to 225
    • Site details revised at 3 of 171 sites
    v79
  25. Study sites revised (171)v78
  26. Site details revised at 1 of 171 sitesv77
  27. Re-verified, no change to tracked fieldsv76
  28. Site contacts updated at 1 of 171 sitesv75
  29. 2 versions Re-verified since Jul 28, 2023, no change to tracked fieldsv73-v74
  30. Site details revised at 2 of 171 sitesv72
  31. Study sites revised (171)v71
  32. Study sites: 169 to 171v70
  33. Study sites: 166 to 169v69
  34. Study sites: 164 to 166v68
  35. Study sites: 161 to 164v67
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
441 trials monitored
See 30 trials at risk
Non-Hodgkin Lymphoma
2,027 trials monitored
See 116 trials at risk
DLBCL
710 trials monitored
See 46 trials at risk
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.
Trial Details
NCT Number NCT04404283
Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer
Conditions
(from sponsor)		 Diffuse Large B-cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov